Diana Nolazco-Avalos

Dr. Diana Nolazco-Avalos

UANL, Nuevo Leon, Mexico
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
Diana Nolazco-AvalosDiana Nolazco-Avalos
Diana Nolazco-Avalos
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
CMCynthia Gabriela Martinez-Liu
Cynthia Gabriela Martinez-Liu
KGKame Galan-Huerta
Kame Galan-Huerta
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors’ serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18–49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.

30 November 2020 in medRxiv
Verified
Preprint
Open access
PDF file
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
Diana Nolazco-AvalosDiana Nolazco-Avalos
Diana Nolazco-Avalos
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
CMCynthia Martinez-Liu
Cynthia Martinez-Liu
RTRogelio Cazares Taméz
Rogelio Cazares Taméz
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
Summary: Background: The progression and distribution of SARS-CoV-2 is unknown because typically only symptomatic individuals are diagnosed. Aim: We evaluated the seroprevalence of anti-SARS-CoV-2 in blood donors in Nuevo Leon, Mexico as a strategy for asymptomatic case detection of COVID-19 and epidemic progression. Methods/Materials: We tested 1968 blood donors that attended two regional donation centers in Northeast Mexico from January 1 st to August 30, 2020, to identify anti-SARS-CoV-2 IgG by chemiluminescent immunoassay. Additionally, routine tests for donors including Brucella, Chagas, HCV, VDRL, HIV-1, and HBsAg identification were performed. Results: We found 77 donors reactive for anti-SARS-CoV-2 IgG (seroprevalence 3.99%) and none of them had reported recent COVID-19 symptoms. Donors aged 18 to 49 years (89.5%) were more likely to be seropositive compared to those aged 50 years or older (10.5%) (P<0.001). Prevalence of antibodies increased each epidemiological (EPI) week, parallel to the report of confirmed cases by RT-PCR, identifying the highest prevalence between EPI week 33 and 35 (10.2% to 19%). The metropolitan area of Monterrey recorded the highest number of cases. Routine tests showed that the prevalence of anti-Brucella was 0.13%, anti-HCV 0.5%, anti-HIV-1-2 0.14%, HBsAg 0.16%, Chagas 0.48% and syphilis 1.06%. Conclusions: There is a growing trend of seroprevalence over time, parallel to the constantly increasing epidemic curve in our region and it was higher under 49 years of age associated with asymptomatic infection in donors from the Nuevo Leon area. Detection of anti-SARS-CoV-2 in blood donors is a potential tool for tracking the progression and identifying population exposure during the SARS-CoV-2 outbreak.